NEWARK, Del., July 27, 2026 /PRNewswire/ -- The Cell Therapy Manufacturing Market is projected to witness rapid expansion as the global biopharmaceutical industry accelerates commercialization of advanced cell therapies and regenerative medicines. According to Future Market Insights (FMI), the market is expected to grow from USD 6.2 billion in 2026 to USD 23.2 billion by 2036, registering a 14.1% CAGR during the forecast period. Rising approvals of cell-based therapies, expanding commercial GMP manufacturing capacity, increasing adoption of automated closed processing systems, and growing investment in advanced biologics manufacturing are expected to fuel sustained market growth.

The market is anticipated to generate an incremental opportunity of USD 17.0 billion between 2026 and 2036. Increasing late-stage clinical programs, rising demand for contract development and manufacturing organizations (CDMOs), and growing commercialization of personalized therapies continue to strengthen the global cell therapy manufacturing ecosystem.

Key Cell Therapy Manufacturing Market Highlights at a Glance

• Market Size (2026): USD 6.2 Billion
• Forecast Market Size (2036): USD 23.2 Billion
• Forecast Period: 2026–2036
• CAGR (2026–2036): 14.1%
• Incremental Opportunity: USD 17.0 Billion
• Leading Manufacturing Scale: Commercial Scale Manufacturing (58.0% Market Share in 2026)
• Leading Technology: Viral Vector Production (32.0% Market Share in 2026)
• Fastest-growing Country: India (17.2% CAGR)
• Second Fastest-growing Country: Japan (16.4% CAGR)
• Key Segments Covered: Manufacturing Scale, Technology, Therapy Type, Workflow, End User, Region
• Report Pages: 315
• Last Updated: June 05, 2026
• Reviewed by: Anurag Sharma

Get Detailed Market Forecasts, Competitive Benchmarking, and Capacity Expansion Insights:

https://www.futuremarketinsights.com/reports/sample/rep-gb-15536

Why Is the Cell Therapy Manufacturing Market Growing?

The market continues to expand as approved cell therapies transition from clinical development to commercial production, requiring highly controlled Good Manufacturing Practice (GMP) facilities capable of delivering consistent, patient-specific therapies.

Growing investment in regenerative medicine, increasing approvals of CAR-T cell therapies and other advanced therapeutics, and rising demand for automated manufacturing platforms are driving global expansion.

Key Growth Drivers

• Rising commercialization of cell therapies.
• Expansion of GMP manufacturing infrastructure.
• Increasing adoption of automated closed processing systems.
• Growing investment in regenerative medicine.
• Rising demand for viral vector manufacturing.
• Expansion of late-stage clinical pipelines.
• Increasing outsourcing to specialized CDMOs.
• Growing emphasis on quality control and regulatory compliance.

As personalized medicine becomes more widely adopted, demand for scalable and compliant manufacturing solutions is expected to remain strong throughout the forecast period.

According to Anurag Sharma, Principal Consultant at Future Market Insights, "Cell therapy manufacturing is becoming a control challenge before it becomes a capacity challenge. Therapy developers increasingly require robust batch identity, automated processing, and faster product release. Manufacturers that combine scalable GMP operations with regulatory expertise will be best positioned to support commercial launches."

Why Does Commercial Scale Manufacturing Lead the Market?

Commercial Scale Manufacturing accounts for 58.0% of global market demand in 2026, making it the leading manufacturing segment.

As more cell therapies receive regulatory approvals, manufacturers are expanding validated GMP facilities capable of supporting commercial production while ensuring consistent product quality and supply continuity.

Manufacturing Scale Highlights

• Commercial-scale manufacturing dominates production demand.
• Approved therapies require validated GMP processes.
• Large-scale facilities improve manufacturing efficiency.
• Commercial capacity supports growing patient demand.

Why Does Viral Vector Production Dominate Technology?

Viral Vector Production accounts for 32.0% of market demand in 2026, supported by its essential role in gene transfer for genetically engineered cell therapies.

Growing adoption of CAR-T therapies, gene-modified immune cell treatments, and advanced regenerative medicine continues driving investment in viral vector manufacturing capabilities.

Technology Highlights

• Viral vectors remain central to engineered cell therapies.
• High-quality gene transfer improves therapeutic performance.
• Advanced manufacturing supports regulatory compliance.
• Growing demand encourages expansion of production capacity.

How Are Advanced Manufacturing Technologies Transforming Cell Therapy Production?

Automation and digital manufacturing technologies are improving efficiency, consistency, and scalability across the cell therapy manufacturing process.

Closed processing systems, advanced analytics, digital quality control, and automated cell handling are helping manufacturers reduce contamination risks, improve batch consistency, and accelerate product release.

Technology Trends

• Expansion of automated closed-system manufacturing.
• Growing use of digital quality analytics.
• Increased investment in GMP automation.
• Rising adoption of advanced fill-finish technologies.
• Expansion of cell banking and cryopreservation infrastructure.
• Greater emphasis on process standardization.

Access the Complete Report in PDF Format:

https://www.futuremarketinsights.com/reports/brochure/rep-gb-15536

Market Dynamics

Market Drivers

Growing approvals of cell therapies, increasing investment in regenerative medicine, expansion of commercial GMP manufacturing, rising demand for viral vectors, growing outsourcing to CDMOs, and increasing regulatory focus on product quality continue driving market growth.

Market Restraints

High manufacturing costs, complex regulatory requirements, limited GMP production capacity, supply chain challenges, workforce shortages, and lengthy technology transfer processes continue presenting challenges for manufacturers.

Market Trends

Innovation continues reshaping the cell therapy manufacturing landscape.

Major trends include:

• Expansion of commercial GMP facilities.
• Increasing adoption of automated manufacturing systems.
• Growth in viral vector production capacity.
• Rising investment in digital manufacturing technologies.
• Strategic partnerships between therapy developers and CDMOs.
• Growing focus on supply chain resilience.

Regional and Country Outlook

The United States remains the largest market, supported by a high volume of approved cell therapies, advanced GMP infrastructure, and significant investment in regenerative medicine research.

India is projected to be the fastest-growing market, registering a 17.2% CAGR, driven by expanding biopharmaceutical manufacturing capabilities, increasing CDMO activity, and favorable government support for biotechnology.

Japan is expected to record a 16.4% CAGR, supported by accelerated regenerative medicine initiatives, advanced healthcare infrastructure, and strong investment in cell therapy commercialization.

China, Germany, France, and the United Kingdom continue to strengthen their manufacturing capabilities through investments in advanced biologics production and GMP infrastructure.

Competitive Landscape

Competition in the Cell Therapy Manufacturing Market is centered on GMP manufacturing capacity, automation technologies, regulatory expertise, viral vector production capabilities, and commercial-scale manufacturing infrastructure.

Leading companies continue expanding production facilities, investing in advanced manufacturing technologies, and forming strategic partnerships with biotechnology innovators to support the commercialization of next-generation cell therapies.

Key Companies

• Lonza Group
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• FUJIFILM Corporation
• Cellares Corporation
• OmniaBio Inc.
• Minaris Advanced Therapies

Frequently Asked Questions

1. What is the projected size of the Cell Therapy Manufacturing Market by 2036?

The global Cell Therapy Manufacturing Market is projected to reach USD 23.2 billion by 2036, growing from USD 6.2 billion in 2026.

2. What is the expected CAGR of the Cell Therapy Manufacturing Market?

The market is forecast to expand at a 14.1% CAGR between 2026 and 2036.

3. Which manufacturing scale dominates the market?

Commercial Scale Manufacturing leads the market with a 58.0% share in 2026.

4. Which technology holds the largest market share?

Viral Vector Production dominates the market, accounting for 32.0% of total technology demand in 2026.

5. What factors are driving market growth?

Growing commercialization of cell therapies, expansion of GMP manufacturing facilities, increasing adoption of automated closed processing systems, rising demand for viral vector production, expanding regenerative medicine pipelines, and greater outsourcing to CDMOs are driving global market growth.

Explore the Latest Healthcare Industry Analysis Now:      

https://www.futuremarketinsights.com/industry-analysis/healthcare       

FMI Custom Research: Strategic Intelligence for Confident Decision-Making     

In today's rapidly evolving business environment, leadership teams need more than market data—they need clear, actionable intelligence tailored to their strategic objectives. FMI's Custom Research solutions are designed around the specific business questions organizations need answered, enabling executives to evaluate growth opportunities, validate investments, assess competitive dynamics, and reduce uncertainty before making critical decisions. By combining deep industry expertise, primary research, and proprietary market intelligence, FMI delivers insights that help organizations move from assumptions to evidence-based strategies with greater speed and confidence.     

Key Executive Benefits     

• Decision-Ready Insights: Research tailored to your specific business challenges, growth plans, and investment priorities.     

• Reduced Strategic Risk: Validate market opportunities, customer demand, and competitive positioning before committing resources.     

• Market Entry Confidence: Assess opportunity size, regulatory barriers, channel dynamics, and competitive landscapes with precision.     

• Competitive Advantage: Gain proprietary intelligence unavailable through syndicated reports or internal datasets.     

• Faster Growth Decisions: Accelerate expansion, product development, portfolio optimization, and investment planning.     

• Primary Market Validation: Access real-world customer, buyer, and stakeholder insights that support high-confidence decision-making.     

• Global Industry Expertise: Powered by 100+ analysts, 20,000+ published reports, and 1.6 million+ hours of research experience.     

• Proven Track Record: Over 7,000 market-entry engagements completed across six regions and 14 industry sectors with strong client retention.     

Business Impact     

FMI helps organizations transform market complexity into strategic clarity, enabling leadership teams to identify growth opportunities faster, optimize resource allocation, strengthen competitive positioning, and make high-stakes business decisions with confidence.     

To explore how FMI Custom Research can support your strategic priorities, please connect with our team at - sales@futuremarketinsights.com      

Related Reports:     

• Analgesics Market - https://www.futuremarketinsights.com/reports/analgesics-market 
• Lung Cancer Therapeutics Market - https://www.futuremarketinsights.com/reports/lung-cancer-therapeutics-market 
• Latex & Occupational Allergy Market - https://www.futuremarketinsights.com/reports/latex-and-occupational-allergy-market 
• Pediatric Allergy Care Market - https://www.futuremarketinsights.com/reports/pediatric-allergy-care-market 
• Genital Herpes Treatment Market - https://www.futuremarketinsights.com/reports/genital-herpes-treatment-market 

About Future Market Insights (FMI)      

Future Market Insights (FMI) delivers actionable, decision-focused market intelligence that goes beyond traditional research reports. The company provides:      

• In-depth pricing and cost benchmarking analysis      

• Demand forecasting based on real industry inputs      

• Procurement and buyer behavior insights      

• Supply chain and trade flow intelligence      

• Technology and application trend analysis across industries      

FMI follows a robust bottom-up research methodology, combining insights from industry experts, procurement leaders, manufacturers, and technical professionals to ensure accurate and practical market intelligence.      

For Press & Corporate Inquiries       

Rahul Singh        

AVP - Marketing and Growth Strategy        

Future Market Insights, Inc.        

+91 8600020075        

For Sales - sales@futuremarketinsights.com        

For Media - Rahul.singh@futuremarketinsights.com        

For web - https://www.futuremarketinsights.com/        

For Web - https://www.factmr.com/ 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/usa-cell-therapy-manufacturing-market-highlights-lonza-group-as-global-market-reaches-usd-23-2-billion-by-2036-at-14-1-cagr--future-market-insights-302835418.html